| 000 | 03446nam a22005415i 4500 | ||
|---|---|---|---|
| 001 | 978-3-319-75184-9 | ||
| 003 | DE-He213 | ||
| 005 | 20210201191438.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 180404s2018 gw | s |||| 0|eng d | ||
| 020 |
_a9783319751849 _9978-3-319-75184-9 |
||
| 050 | 4 | _aRC261-271 | |
| 072 | 7 |
_aMJCL _2bicssc |
|
| 072 | 7 |
_aMED062000 _2bisacsh |
|
| 072 | 7 |
_aMJCL _2thema |
|
| 082 | 0 | 4 |
_a614.5999 _223 |
| 245 | 1 | 0 |
_aResistance of Targeted Therapies Excluding Antibodies for Lymphomas _h[electronic resource] / _cedited by Andrés J. M. Ferreri. |
| 250 | _a1st ed. 2018. | ||
| 264 | 1 |
_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2018. |
|
| 300 |
_aXIII, 138 p. 14 illus., 13 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 |
_aResistance to Targeted Anti-Cancer Therapeutics, _x2196-5501 ; _v17 |
|
| 500 | _aAcceso multiusuario | ||
| 505 | 0 | _aChapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents. | |
| 520 | _aIn the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. . | ||
| 541 |
_fUABC ; _cTemporal ; _d01/01/2021-12/31/2023. |
||
| 650 | 0 | _aCancer research. | |
| 650 | 0 | _aMolecular biology. | |
| 650 | 1 | 4 |
_aCancer Research. _0https://scigraph.springernature.com/ontologies/product-market-codes/B11001 |
| 650 | 2 | 4 |
_aMolecular Medicine. _0https://scigraph.springernature.com/ontologies/product-market-codes/B1700X |
| 700 | 1 |
_aFerreri, Andrés J. M. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer Nature eBook | |
| 776 | 0 | 8 |
_iPrinted edition: _z9783319751832 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783319751856 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030091651 |
| 830 | 0 |
_aResistance to Targeted Anti-Cancer Therapeutics, _x2196-5501 ; _v17 |
|
| 856 | 4 | 0 |
_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-75184-9 |
| 912 | _aZDB-2-SBL | ||
| 912 | _aZDB-2-SXB | ||
| 942 | _cLIBRO_ELEC | ||
| 999 |
_c243582 _d243581 |
||